Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
Fengchun ZhangJie ZhengYang LiGuochun WangMingjun WangYin SuJieruo GuXingfu LiDamon L BassMyron ChuPaula CurtisKathleen DeRoseRegina KurraschJenny LowePaige MeizlikDavid A RothPublished in: RMD open (2022)
Favourable safety profile and disease control appeared to be maintained in patients with SLE in China for ≤6 years, consistent with previous belimumab studies.